| Literature DB >> 26702083 |
Erin K Donaho1, Andrea C Hall2, Jennifer A Gass2, Macarthur A Elayda3, Vei-Vei Lee3, Shreda Paire4, Deborah E Meyers3.
Abstract
BACKGROUND: Heart failure (HF) patients have high rates of hospitalization and rehospitalization. METHODS ANDEntities:
Keywords: diuretics; drugs; heart failure; nursing; pharmacy; readmission; transition care
Mesh:
Year: 2015 PMID: 26702083 PMCID: PMC4845270 DOI: 10.1161/JAHA.115.002296
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Baseline Characteristics of the Patients Referred to the Clinic
| Characteristic | Seen (N=114) | Not Seen (N=55) |
|
|---|---|---|---|
| Age, mean (range) | 59 (17–87) | 59.9 (26–90) | |
| Sex (male) | 55 (48%) | 33 (61%) | 0.12 |
| Ethnicity | |||
| Hispanic/other | 10.5% | 7.3% | |
| African American | 65.8% | 52.7% | |
| Caucasian | 20.2% | 34.5% | |
| Declined identification | 3.5% | 5.5% | |
| Insurance status | |||
| Medicare | 17.5% | 23.6% | |
| Medicaid | 63.2% | 54.5% | |
| Private insurance | 12.3% | 12.7% | |
| Uninsured/self‐pay | 7.0% | 9.2% | |
| Diabetes mellitus | 64 (56%) | 30 (55%) | 0.85 |
| Coronary artery disease | 62 (54%) | 28 (51%) | 0.67 |
| Hypertension | 98 (86%) | 38 (69%) | 0.01 |
| Dyslipidemia | 67 (59%) | 23 (42%) | 0.04 |
| OSA | 27 (24%) | 8 (15%) | 0.17 |
| COPD | 26 (23%) | 10 (18%) | 0.49 |
| Pulmonary hypertension | 14 (12%) | 6 (11%) | 0.80 |
| Advanced renal disease | |||
| CRI (SCr >1.5, not ESRD) | 37 (32%) | 16 (29%) | 0.66 |
| ESRD | 10 (9%) | 3 (5%) | 0.45 |
| Body mass index >35 | 48 (42%) | 17 (31%) | 0.14 |
| Atrial fibrillation | 30 (26%) | 14 (25%) | 0.90 |
| Tobacco use | 24 (21%) | 16 (31%) | 0.33 |
COPD indicates chronic obstructive pulmonary disease; CRI, chronic renal insufficiency; ESRD, end‐stage renal disease; OSA, obstructive sleep apnea; SCr, serum creatinine.
Heart Failure Characteristics of the Patients Who Visited the Clinic
| Structural Classification of Heart Failure | N (114 Total) | EF (Mean %) | RVSP (Mean) |
|---|---|---|---|
| HFrEF | 52 | 25.9±8.09 | 44.7±10.77 |
| HFpEF | 21 | 51.7±6.79 | NR |
| Biventricular dysfunction | 34 | 22.4±5.67 | 47.9±13.75 |
| Isolated RV systolic dysfunction | 7 | 60±8.16 | 78.0±22.75 |
EF indicates ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; NR, normal range; RV, right ventricular; RVSP, right ventricular systolic pressure.
RV dysfunction as described qualitatively on the echocardiogram.
New York Heart Association (NYHA) Functional Classification Across Visits
| NYHA Class | Visit 1 (N=114) | Visit 2 (N=87) |
|---|---|---|
| II | 19 (17%) | 18 (20%) |
| III | 89 (78%) | 63 (69%) |
| IV | 6 (5%) | 6 (7%) |
NYHA classification data unavailable for 4 patients at visit 2.
Figure 1Volume status at each clinic visit.
Figure 2Medication reconciliation errors (MRE) at each clinic visit.
Medication Titrations at Each Clinic Visit
| Medication Category | Visit 1 (N=114) | Visit 2 (N=91) |
|---|---|---|
| Diuretic, PO/parenteral IV | 51 (45%)/6 (5%) | 34 (37%)/3 (3%) |
| ACE inhibitors/ARBs | 33 (29%) | 25 (27%) |
| Hydralazine | 21 (18%) | 11 (12%) |
| Beta blockers | 48 (42%) | 20 (22%) |
| Isordil | 11 (10%) | 9 (10%) |
| Digoxin | 4 (3.5%) | 2 (2%) |
| Potassium | 12 (11%) | 12 (13%) |
| Aldosterone antagonist | 18 (16%) | 13 (14%) |
| Average No. of HF medication changes per visit | 1.7 | 1.4 |
ACE indicates angiotensin‐converting enzyme; ARB, angiotensin II receptor blocker; HF, heart failure; IV, intravenous administration; PO, oral administration.